Skip to main content
. 2019 Nov 21;20:637. doi: 10.1186/s13063-019-3740-6

Fig. 1.

Fig. 1

Flow chart showing the study design of the placebo-controlled, double-blind phase of the tamoxifen in Duchenne muscular dystrophy (TAMDMD) study. *For those patients who do not enter the open-label extension phase. RCT randomized controlled trial, V visit